checkAd

    DGAP-Adhoc  365  0 Kommentare Vita 34 AG: Management and supervisory board rely on continuity in the corporation


    Vita 34 AG / Key word(s): Change of Personnel

    01.08.2014 18:27

    Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
    by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Vita 34 AG: Management and supervisory board rely on continuity in the
    corporation

    - Management contract extended: Dr. André Gerth reappointed as CEO until
    2018

    - Internal changeover in supervisory board: Dr. Giering takes seat of
    chairman of supervisory board; previous chairman Dr. Födisch remains
    member of the board

    Leipzig, 1 August 2014 -Vita 34 AG (WKN A0BL84), the largest private stem
    cell bank in the German-speaking countries, provides for continuity in the
    corporation by reappointing Dr. André Gerth as CEO until 2018 and an
    internal changeover in the supervisory board.

    In today's meeting the supervisory board of Vita 34 AG has reappointed Dr.
    Gerth as the corporation's CEO from 1 August 2014 to 31 December 2018. The
    supervisory board thus expresses once again its confidence in Dr. Gerth and
    recognizes his previous performance as CEO of Vita 34 AG. Beyond that, Dr.
    Gerth emphasizes his commitment to Vita 34 AG by extending the lock-up
    agreement for his Vita 34 shares by another 18 months. The management board
    appreciates Dr. Gerth's clear proof of confidence.

    At the same time, the supervisory board elected Dr. Hans-Georg Giering, so
    far vice chairman of the supervisory board, the new chairman. He takes over
    the position from Dr. Holger Födisch with immediate effect. Dr. Giering has
    approved expertise from acting as the CEO of a quoted, successful company
    for almost 15 years. He will contribute this experience to his new position
    as the chairman of the supervisory board at Vita 34 AG. Dr. Födisch will
    continue to actively support the corporation as vice chairman of the
    supervisory board in the future.


    01.08.2014 The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------------

    Language: English
    Company: Vita 34 AG
    Deutscher Platz 5a
    04103 Leipzig
    Germany
    Phone: +49(0341)48792-40
    Fax: +49(0341)48792-39
    E-mail: ir@vita34.de
    Internet: www.vita34.de
    ISIN: DE000A0BL849
    WKN: A0BL84
    Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
    in Berlin, Düsseldorf, Hamburg, München, Stuttgart

    End of Announcement DGAP News-Service

    ---------------------------------------------------------------------------



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Vita 34 AG: Management and supervisory board rely on continuity in the corporation Vita 34 AG / Key word(s): Change of Personnel 01.08.2014 18:27 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer